Showing 2751-2760 of 4166 results for "".
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patientshttps://modernod.com/news/sight-sciences-announces-publication-of-clinical-data-demonstrating-standalone-effectiveness-of-the-omni-surgical-system-in-pseudophakic-glaucoma-patients-with-uncontrolled-pressure-following-a-previous-combination-cataract-stent-procedure/2481221/Sight Sciences announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System as a minimally invasive, implant-free standalone (not in combination with cataract surgery) glaucoma procedure for pseudophaki
- Zeiss to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software Applicationshttps://modernod.com/news/zeiss-to-unveil-clinical-insights-supporting-the-value-of-new-data-driven-digital-workflow-solutions-and-software-applications/2480752/Zeiss Medical Technology will host ZEISS Innovation Day on April 7, 2022, showcasing clinical perspectives from global experts with first-hand experience integrating devices, data and software applications.
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- Nicox’s Partner Ocumension Therapeutics Initiates Zerviate Phase 3 Clinical Trial in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-therapeutics-initiates-zerviate-phase-3-clinical-trial-in-china/2478704/Nicox SA announced that its partner, Ocumension Therapeutics, has initiated a phase 3 clinical trial in China with Zerviate, the first and only topical ocular formulation of the anti
- Pooled Analysis of Data from Two Phase 3 Clinical Trials of Upneeq for Acquired Ptosis Publishedhttps://modernod.com/news/pooled-analysis-of-data-from-two-phase-3-clinical-trials-of-upneeq-for-acquired-ptosis-published/2478357/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that JAMA Ophthalmology has published pooled analysis of data from two phase 3 clinical trials of Upneeq (oxymetazoline hydrochloride ophthalmic solution) 0.1% for treatment of acquired blepharoptosis (
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- SIFI Reports Positive Results From 044/si Phase 3 Clinical Trial of Netildex Gelhttps://modernod.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/SIFI has announced the conclusion of a phase 3 clinical trial aimed at demonstrating the noninferiority of Netildex gel administered twice daily (BID) vs. Netildex solution administered four ti
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- Mayo Clinic, CommonSpirit, and Mass General Feel Hit From COVID-19 in Q1https://modernod.com/news/mayo-clinic-commonspirit-and-mass-general-feel-hit-from-covid-19-in-q1/2477795/Major health systems the Mayo Clinic, CommonSpirit Health, and Mass General Brigham revealed the first details on how the COVID-19 pandemic is hitting them financially, with some systems reporting millions in losses, according to a FierceHealthcare